Prime Medicine (NASDAQ:PRME) reported full-year 2025 financial results on Tuesday, signaling a strategic shift toward commercial-stage readiness as its "search-and-replace" gene editing platform achieves its first human clinical validations.
The Cambridge, Massachusetts-based biotech reported a net loss of $201.1 million for the year ended December 31, 2025.
This loss reflects a heavy investment in its Prime Editing platform, with research and development (R&D) expenses totaling $160.6 million.
General and administrative (G&A) costs were reported at $52.3 million.
The company ended the year with $191.4 million in cash, cash equivalents, and investments, a position providing capital for ongoing clinical development.
The financial report follows a watershed moment for the company’s lead program, PM359, an ex vivo therapy for Chronic Granulomatous Disease (CGD).
The company announced the publication of PM359 Phase 1/2 clinical data in The New England Journal of Medicine, a milestone that supports its ongoing engagement with the FDA.